Reuters logo
BRIEF-AstraZeneca says ‍pan-Canadian oncology drug review has provided positive clinical recommendation for reimbursement of Lynparza ​
September 21, 2017 / 12:08 PM / 3 months ago

BRIEF-AstraZeneca says ‍pan-Canadian oncology drug review has provided positive clinical recommendation for reimbursement of Lynparza ​

Sept 21 (Reuters) - AstraZeneca Plc

* AstraZeneca Plc says ‍pan-Canadian oncology drug review (PCODR) has provided an overwhelmingly positive clinical recommendation for reimbursement of Lynparza (olaparib)​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below